Dystonia: A Leading Neurological Movement Disorder

Dystonia is the third leading movement disorder arising mainly from the damage of basal ganglia or other parts of the brain that control movements. The objective of this review is to represent the detailed profile of dystonia. A computerized literature review was conducted in authentic scientific databases including PubMed, Google Scholar, Scopus, Science Direct and National Institutes of Health (NIH) etc. Terms searched included dystonia, risk factors, etiologies, clinical features, classification, pathology, guidelines, treatment strategies, primary and secondary dystonia. Initially, 97 articles and 9 books were extracted but finally, 64 articles and 7 books were used. After analysis, we found that causes of dystonia could be acquired or inherited and dystonia can be classified based on age at onset, etiology, and distribution of the affected body parts. The risk factors of this heterogeneous disorder could be trauma, thyroid disorder, hypertension, life habits, occupation, use of drugs and genetics. A significant number of articles were found which signify the ability of brainstem and cerebellar pathology to trigger the symptoms of dystonia. Since antipsychotic drugs are the most commonly prescribed among the people with intellectual disability (ID), therefore they possess a greater risk to experience antipsychotic drugs-induced movement side effects including acute dystonia, parkinsonism, tardive dyskinesia, and akathisia. Depending on various manifestations and causes, there are several treatment options including oral medications, intramuscular injection of botulinum toxin, neurosurgical procedures and occupational therapy

A systematic review on COVID-19 vaccine strategies, their effectiveness, and issues

COVID-19 vaccines are indispensable, with the number of cases and mortality still rising, and currently no medicines are routinely available for reducing morbidity and mortality, apart from dexamethasone, although others are being trialed and launched. To date, only a limited number of vaccines have been given emergency use authorization by the US Food and Drug Administration and the European Medicines Agency. There is a need to systematically review the existing vaccine candidates and investigate their safety, efficacy, immunogenicity, unwanted events, and limitations. The review was undertaken by searching online databases, i.e., Google Scholar, PubMed, and ScienceDirect, with finally 59 studies selected. Our findings showed several types of vaccine candidates with different strategies against SARS-CoV-2, including inactivated, mRNA-based, recombinant, and nanoparticle-based vaccines, are being developed and launched. We have compared these vaccines in terms of their efficacy, side effects, and seroconversion based on data reported in the literature. We found mRNA vaccines appeared to have better efficacy, and inactivated ones had fewer side effects and similar seroconversion in all types of vaccines. Overall, global variant surveillance and systematic tweaking of vaccines, coupled with the evaluation and administering vaccines with the same or different technology in successive doses along with homologous and heterologous prime-booster strategy, have become essential to impede the pandemic. Their effectiveness appreciably outweighs any concerns with any adverse events

テロメア イジ ノ クミカエ イゾン テキ ケイロ ニ オケル ヒストン ダツ アセチル カ コウソ 9 ニ ヨル PML コウゾウタイ ノ ケイセイ セイギョ

熊本大

テロメア イジ ノ クミカエ イゾン テキ ケイロ ニ オケル ヒストン ダツ アセチル カ コウソ 9 ニ ヨル PML コウゾウタイ ノ ケイセイ セイギョ

博士(医学)熊本大

Phytochemical Screening and Antioxidant Profile of Syngonium podophyllum Schott Stems: A Fecund Phytopharmakon

Background: Oxidative stress has been shown to play an imperative role in copious disease pathology. Plants are acquaintances of mankind and mainstay for the treatment of oxidative stress linked disorders. Therefore, the objective of the existing study was to assess the phytochemical contents and antioxidant activity of crude methanol extract (CME), n-hexane (NHF), chloroform (CLF), ethyl acetate (EAF) and aqueous (AQF) fractions of Syngonium podophyllum (S. podophyllum) Schott stems.Methods: The S. podophyllum Schott stems extract and its fractions were subjected to phytochemical analysis to detect the presence of alkaloids, carbohydrates, saponins, tannins, resins, flavonoids and steroids. The antioxidant profile was determined by total antioxidant activity (TAA), reducing power activity (RPA) and DPPH (2,2-diphenyl-1-picrylhydrazyl) radical scavenging activity tests and correlated with the estimation of total flavonoid content (TFC).Results: In CME and its fractions of S. podophyllum Schott stems all of the tested phytoconstituents (alkaloids, tannins, resins, flavonoids and steroids) were detected at various concentration except carbohydrates and saponins. In TAA test, highest absorbance (2.18 nm) which is a measure of high antioxidant activity was reported in CME compared to remaining fractions. Likely in RPA test with respect to all fractions similar denouements were found for CME (3.29 nm). In case of DPPH scavenging test, the CME showed highest scavenging activity (77.89 %) having IC50 of 41.02 ?g/ml (P < 0.05) compared to remaining fractions. The antioxidant activity is possibly due to the highest TFC (7.45 mg of GAE/g of dried extract) reported in CME compared to existing fractions.Conclusion: The aforementioned outcomes recommend that CME of S. podophyllum Schott stems can be a possible cradle of plant-derived natural antioxidant and can be used to avert diseases linked with free radicals

COVID-19 diagnostics: Current and Prospective Tools

COVID-19 presents a major challenge to the current healthcare system worldwide while exposing multifaceted problems underlying the infrastructure as well as the preparedness of disaster management in relation to emerging infectious disease. Timely detection and confinement of infected cases present the first step in combating COVID-19. In this review, we explore different COVID-19 diagnostic methods that are available or under investigation. Cell culture followed by an indirect fluorescent antibody presents the most accurate method for SARS-CoV-2 detection through regulatory and commercial infeasibility prohibits its general implementation. Diagnosis by radiologic imaging along with reverse transcriptase PCR is widespread and is considered as standard while isothermal amplification methods are currently on the verge. CRISPR-Cas and microfluidics adds new dimension to SARS-CoV-2 detection. Moreover, immunoassays such as ELISA, LFIA, neutralization assay, and chemiluminescent assay, can also be used for detection and surveillance. Additionally, NGS and metagenomic analysis are smoothing the obscurities further in this challenge

Development and performance evaluation of a rapid in-house ELISA for retrospective serosurveillance of SARS-CoV-2.

BackgroundIn the ongoing pandemic situation of COVID-19, serological tests can complement the molecular diagnostic methods, and can be one of the important tools of sero-surveillance and vaccine evaluation.AimTo develop and evaluate a rapid SARS-CoV-2 specific ELISA for detection of anti-SARS-CoV2 IgG from patients' biological samples.MethodsIn order to develop this ELISA, three panels of samples (n = 184) have been used: panel 1 (n = 19) and panel 2 (n = 60) were collected from RT-PCR positive patients within 14 and after 14 days of onset of clinical symptoms, respectively; whereas panel 3 consisted of negative samples (n = 105) collected either from healthy donors or pre-pandemic dengue patients. As a capturing agent full-length SARS-CoV2 specific recombinant nucleocapsid was immobilized. Commercial SARS-CoV2 IgG kit based on chemiluminescent assay was used for the selection of samples and optimization of the assay. The threshold cut-off point, inter-assay and intra-assay variations were determined.ResultsThe incubation/reaction time was set at a total of 30 minutes with the sensitivity of 84% (95% confidence interval, CI, 60.4%, 96.6%) and 98% (95% CI, 91.1%, 100.0%), for panel 1 and 2, respectively; with overall 94.9% sensitivity (95% CI 87.5%, 98.6%). Moreover, the clinical specificity was 97.1% (95% CI, 91.9%, 99.4%) with no cross reaction with dengue samples. The overall positive and negative predictive values are 96.2% (95% CI 89.2%, 99.2%) and 96.2% (95% CI, 90.6% 99.0%), respectively. In-house ELISA demonstrated 100% positive and negative percent agreement with Elecsys Anti-SARS-CoV-2, with Cohen's kappa value of 1.00 (very strong agreement), while comparing 13 positive and 17 negative confirmed cases.ConclusionThe assay is rapid and can be applied as one of the early and retrospective sero-monitoring tools in all over the affected areas

Breast cancer management in the era of Covid-19; key issues, contemporary strategies, and future implications

During the COVID-19 pandemic, several priority diseases were not getting sufficient attention. Whilst breast cancer is a fatal disease affecting millions worldwide, identification and management of these patients did not initially attract critical attention to minimize the impact of lockdown, post-lockdown, and other measures. Breast cancer patients' conditions may not remain stable without proper care, worsening their prognosis. Proper care includes the timely instigation of surgery, systemic therapy, and psychological support. This includes low- and middle-income countries where there are already concerns with available personnel and medicines to adequately identify and treat these patients. Consequently, there was a need to summarize the current scenario regarding managing breast cancer care during COVID-19 across all countries, including any guidelines developed. We systematically searched three scientific databases and found 76 eligible articles covering the medical strategies of high-income countries versus LMICs. Typically, diagnostic facilities in hospitals were affected at the beginning of the pandemic following the lockdown and other measures. This resulted in more advanced-stage cancers being detected at initial presentation across countries, negatively impacting patient outcomes. Other than increased telemedicine, instigating neo-adjuvant endocrine therapy more often, reducing non-essential visits, and increasing the application of neo-adjuvant chemotherapy to meet the challenges, encouragingly, there was no other significant difference among patients in high-income versus LMICs. Numerous guidelines regarding patient management evolved during the pandemic to address the challenges posed by lockdowns and other measures, which were subsequently adopted by various high-income countries and LMICs to improve patient care. The psychological impact of COVID-19 and associated lockdown measures, especially during the peak of COVID-19 waves, and the subsequent effect on the patient's mental health must also be considered in this high-priority group. We will continue to monitor the situation to provide direction in future pandemics